Summary of the Conference Call for Staily Company Company Overview - Staily is a leading supplier of iodine contrast agents in China, with the largest product scale and variety in the market. The production capacity and output of Iohexol rank among the top in the country. [2][3] Industry Insights - The iodine contrast agent market in China is expected to recover to a scale of 15 billion RMB by 2024, following the impact of centralized procurement in 2021. [6] - The global X-ray contrast agent market accounts for 72.5% of the total contrast agent market, with Iohexol, Iopamidol, and Ioversol holding market shares of 31.5%, 18%, and 14.1% respectively. [5] Key Financial Metrics - The compound annual growth rate (CAGR) of domestic formulation revenue over the past five years reached 161%, increasing from 12 million RMB in 2020 to 558 million RMB in 2024. [4] - Projected revenues for 2025, 2026, and 2027 are 2.504 billion RMB, 2.818 billion RMB, and 3.221 billion RMB respectively, with net profits of 46 million RMB, 169 million RMB, and 322 million RMB. [4][15] Production Capacity and Cost Management - Staily has established over 2,400 tons of raw material capacity, with 1,800 tons certified for domestic and international quality systems. This is expected to increase to 3,000 tons by the end of the year, covering nearly one-third of global demand. [2][8] - Gross margin improvements are attributed to declining iodine prices, increased capacity utilization, and cost reduction through point recovery technology, which has reached original research levels. [11] Internationalization Strategy - Staily is actively promoting the international sales of formulations through the registered advantages and sales network of its Irish subsidiary, IMAX. As of 2024, IMAX's overseas formulation sales reached 86.2 million RMB. [2][3] Future Growth Drivers - The company anticipates a doubling of internal shipment volume from 400 tons to 800 tons over the next 3 to 4 years due to the new production capacity from the intelligent transformation project in Shanghai. [10] - The company is expected to benefit from the completion of European GMP certification for its Shanghai factory, which will enhance production efficiency and reduce costs for overseas markets. [13] Valuation and Investment Potential - As of the last trading day, Staily's closing price was 9.46 RMB, with a total market capitalization of approximately 4.1 billion RMB. The company is projected to have a price-to-earnings ratio of 95x, 24x, and 13x for the years 2025, 2026, and 2027 respectively, indicating a favorable investment value. [15]

Core Viewpoint - The company is positioned as a leading integrated enterprise in the iodine contrast agent market, with a focus on expanding its international strategy and enhancing production capacity to meet growing demand [8][10][12]. Company Overview - The company, Zhejiang Sital Pharmaceutical Co., Ltd., was established in 1997 and listed in 2016, specializing in X-CT non-ionic contrast agents and related products, making it the largest manufacturer in China in terms of product variety and scale [8]. - The company has a clear shareholding structure, with the controlling shareholders being Hu Jian and Hu Jinsheng, who collectively hold 22.33% of the shares [10]. - The company has four major production bases, focusing on releasing production capacity after a phase of significant expansion [12][13]. Revenue and Profitability - The company's revenue has shown steady growth, with total revenue increasing from 1.367 billion yuan in 2020 to an estimated 2.350 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 14.51% [15]. - The iodine contrast agent business contributes approximately 80% of total revenue, with a growth from 1.214 billion yuan in 2020 to 1.870 billion yuan in 2024 [15]. - The company faced profitability pressures due to rising raw material costs, with net profit declining from 239 million yuan in 2020 to a projected loss in 2024, although a recovery is expected in 2025 [17]. Industry Insights - The global iodine contrast agent market is characterized by high barriers to entry and significant concentration, with major players including GE Healthcare and Bayer [21][32]. - The iodine contrast agent market is projected to grow, driven by increasing demand for medical imaging and advancements in healthcare infrastructure, particularly in emerging markets [23][27]. - The company is expected to capture a significant share of the global iodine contrast agent raw material market, with a projected capacity of 3,000 tons by the end of 2025, representing nearly one-third of global demand [36][38]. Production Capacity and Quality - The company has achieved substantial production capacity in iodine contrast agents, with 2,400 tons already built and expected to reach 3,000 tons by the end of 2025 [36][37]. - The company has completed quality certifications for approximately 1,800 tons of its production capacity, ensuring compliance with international standards [37]. - The company’s main products, including Iohexol and Iopamidol, have significant market shares, with sales revenues of 68.28 million USD and 26.16 million USD respectively in 2024 [38][39].

Core Points - The company did not distribute cash dividends or issue bonus shares during the reporting period [3] - The company’s controlling shareholder and actual controller did not change during the reporting period [5] - The company’s subsidiary Tianyuan Pharmaceutical won the bid for the centralized procurement of traditional Chinese medicine in Guangdong [5] - The company received various drug registration certificates and approvals for its products in 2025 [5][6] - The company completed the redemption of its convertible bonds in August 2025 [6] - The company’s subsidiary Haichang Pharmaceutical obtained market access for several raw materials in South Korea and India [6] Financial Data and Indicators - The report indicates that all board members attended the meeting to review the report [2] - The company’s half-year report was disclosed on August 26, 2025, on designated platforms [8] - The company confirmed the accuracy and completeness of the information disclosed in the report [8]

Investment Rating - The report maintains a "Strong Buy" rating for the company [3]. Core Views - The company is expected to overcome operational bottlenecks and improve profitability, moving towards becoming a comprehensive supplier of contrast agents [1][7]. - The management efficiency has improved significantly under the current chairman, with revenue per employee increasing from 550,000 RMB in 2015 to 1,340,000 RMB in 2025 [7][19]. - The company is entering a phase of increased production capacity for iodine contrast agents, with capital expenditures (CAPEX) peak passed and utilization rates expected to rise [7][19]. - The domestic and international demand for contrast agents is expanding, with the company positioned as a key supplier in the iodine contrast agent market [7][27]. Financial Data and Projections - The company is projected to achieve a net profit of 0.7 billion RMB in 2025, 2.3 billion RMB in 2026, and 3.5 billion RMB in 2027, with corresponding price-to-earnings (PE) ratios of 58, 18, and 11 [8][75]. - Revenue is expected to grow from 2.196 billion RMB in 2023 to 3.516 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 15% [8][85]. - The company’s operating profit is forecasted to recover from a loss of 0.054 billion RMB in 2024 to a profit of 0.277 billion RMB in 2026 [8][85]. Market Dynamics - The global market for contrast agents is projected to grow at a compound annual growth rate (CAGR) of 6.8%, with iodine contrast agent demand expected to double in the next decade [7][31]. - The supply of iodine is constrained, with major producers unable to significantly increase output, maintaining a tight balance between supply and demand [22][27]. - The company is positioned as a leading supplier in the iodine contrast agent market, with a comprehensive product range and established customer relationships [7][34]. Production Capacity and Expansion - The company has completed the construction of over 2,400 tons of raw material capacity, with approximately 1,800 tons certified under major quality systems [7][37]. - The company plans to utilize funds from a recent capital increase to expand production capacity for non-ionic CT contrast agents and iodine compounds [37][38]. Competitive Position - The company has a significant market share in iodine contrast agents, with a focus on expanding its product offerings and enhancing its competitive edge through strategic investments [7][34]. - The domestic procurement policies are expected to benefit the company, as it has a strong cost and scale advantage in raw materials [7][57]. International Expansion - The company is leveraging its international platform, IMAX, to enhance its global presence, with sales revenue from overseas operations increasing by 60% year-on-year [72]. - The company anticipates completing EU-GMP certification for its Shanghai facility in 2025, facilitating further international market penetration [72][75].